Allena Pharmaceuticals, Inc. Shareholders Equity and Liabilities (Total)

Shareholders Equity and Liabilities (Total) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Shareholders Equity and Liabilities (Total) growth rates and interactive chart.


Highlights and Quick Summary

  • Shareholders Equity and Liabilities (Total) for the quarter ending March 31, 2022 was $21.7 Million (a -37.47% decrease compared to previous quarter)
  • Year-over-year quarterly Shareholders Equity and Liabilities (Total) decreased by -28.24%
  • Annual Shareholders Equity and Liabilities (Total) for 2021 was $34.8 Million (a -10.72% decrease from previous year)
  • Annual Shareholders Equity and Liabilities (Total) for 2020 was $38.9 Million (a 14.14% increase from previous year)
  • Annual Shareholders Equity and Liabilities (Total) for 2019 was $34.1 Million (a -47.71% decrease from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Shareholders Equity and Liabilities (Total) of Allena Pharmaceuticals, Inc.

Most recent Shareholders Equity and Liabilities (Total)of ALNA including historical data for past 10 years.

Interactive Chart of Shareholders Equity and Liabilities (Total) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Shareholders Equity and Liabilities (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $21.73
2021 $34.76 $43.87 $30.29 $40.47 $34.76
2020 $38.93 $31.97 $29.11 $23.67 $38.93
2019 $34.11 $42.77 $53.58 $54.81 $34.11
2018 $65.23 $73.4 $80.06 $87.57 $65.23
2017 $96.25 $36.26 $0.0 $0.0 $96.25
2016 $0.0 $49.48
2015 $70.0 $70.01

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.